Method for the production of ceftobiprole medocaril
    13.
    发明授权
    Method for the production of ceftobiprole medocaril 有权
    生产头孢匹隆中间体的方法

    公开(公告)号:US09139597B2

    公开(公告)日:2015-09-22

    申请号:US13320430

    申请日:2010-05-25

    摘要: The present invention relates to a method for the production of organic compounds, in particular sodium (6R,7R)-7-[(Z)-2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino-acetylamino]-8-oxo-3-[(E)-(R)-1′-(5-methyl-2-oxo-[1,3]-dioxol-4-ylmethoxycarbonyl)-2-oxo-[1,3′]bipyrrolidinyl-3-ylidenemethyl]-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate (ceftobiprole medocaril), and compounds of the general formula (1) and of the general formula (2), the compounds themselves and intermediates in the production according to the invention.

    摘要翻译: 本发明涉及一种生产有机化合物的方法,特别是(6R,7R)-7 - [(Z)-2-(5-氨基 - [1,2,4]噻二唑-3-基) -2-羟基亚氨基 - 乙酰氨基] -8-氧代-3 - [(E) - (R)-1' - (5-甲基-2-氧代 - [1,3] - 二氧杂环戊烯-4-基甲氧基羰基)-2- 氧基 - [1,3']联吡咯烷基-3-亚基甲基] -5-硫杂-1-氮杂 - 双环[4.2.0]辛-2-烯-2-羧酸酯(头孢噻肟中间体)和通式( 1)和通式(2),本发明的生产中的化合物本身和中间体。

    Purification process
    15.
    发明授权
    Purification process 失效
    净化过程

    公开(公告)号:US06313289B1

    公开(公告)日:2001-11-06

    申请号:US09341542

    申请日:1999-08-04

    IPC分类号: C07D50104

    CPC分类号: C07D501/00

    摘要: Crystalline 2-(amninothiazol-4-yl)-2-(tert.butoxycarbonylmethoxyimino)acetic acid-S-mercapto-benzo-thiazolylester in form of an N,N-dimethylacetamide solvate; a crystalline salt of a 7-[2-(aminothiazol-4-yl)-2-(carboxymethoxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid with an amine of formula N(R1)(R2)(R3), wherein R1, R2, and R3 have various meanings, a crystalline sulphuric acid addition salt of a 7-[2-(2-aminothiazol-4-yl)-2-carboxymethoxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid; and the use of these salts in the production of cefixime, e.g. in form of a trihydrate.

    摘要翻译: N,N-二甲基乙酰胺溶剂化物形式的2-(氨基噻唑-4-基)-2-(叔丁氧基羰基甲氧基亚氨基)乙酸S-巯基 - 苯并噻唑酯的结晶; 7- [2-(氨基噻唑-4-基)-2-(羧基甲氧基亚氨基)乙酰氨基] -3-乙烯基-3-头孢烯-4-羧酸与式N(R1)(R2)的胺的结晶盐, (R3),其中R1,R2和R3具有各种含义,7- [2-(2-氨基噻唑-4-基)-2-羧甲氧基亚氨基)乙酰氨基] -3-乙烯基-3 - 头孢-4-羧酸; 以及这些盐在头孢克肟的生产中的用途。 呈三水合物的形式。

    CRYSTALLINE FORM OF RIVAROXABAN DIHYDRATE
    19.
    发明申请
    CRYSTALLINE FORM OF RIVAROXABAN DIHYDRATE 有权
    RIVAROXABAN DIHYDRATE的结晶形式

    公开(公告)号:US20130245017A1

    公开(公告)日:2013-09-19

    申请号:US13805462

    申请日:2011-07-05

    IPC分类号: C07D413/12

    CPC分类号: C07D413/12 C07D413/14

    摘要: The present invention relates to a novel crystalline dihydrate of Rivaroxaban, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline dehydrate and to processes for preparing and storing said pharmaceutical compositions. The invention also relates to a crystalline formic acid solvate of Rivaroxaban, processes for the preparation of crystalline Rivaroxaban formic acid solvate and to the use of said Rivaroxaban formic acid solvate in the manufacture of the crystalline dihydrate of Rivaroxaban.

    摘要翻译: 本发明涉及一种新型的Rivaroxaban结晶二水合物,其制备方法,包含所述结晶脱水物的药物组合物以及制备和储存所述药物组合物的方法。 本发明还涉及Rivaroxaban的结晶甲酸溶剂化物,制备结晶Rivaroxaban甲酸溶剂合物的方法,以及所述Rivaroxaban甲酸溶剂合物在制造Rivaroxaban结晶二水合物中的用途。